Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers.
More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
